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Abstract
Background: PATRO Children is an ongoing observational, longitudinal, non-interventional, global post-marketing
surveillance study, which is investigating the long-term safety and effectiveness of Omnitrope®, a somatropin
biosimilar to Genotropin®, in children with growth disturbances. The primary endpoint of PATRO Children is long-term
safety and the secondary endpoint is effectiveness, which is assessed by analysing auxological data such as height
(HSDS) and height velocity (HVSDS) standard deviation scores. Here, we report the data from the Italian interim analysis
of PATRO Children data up to August 2015.
Methods: PATRO Children is enrolling children who are diagnosed with conditions of short stature requiring GH
treatment and are receiving Omnitrope®. Adverse events (AEs) are assessed in all Omnitrope®-treated patients.
Height is evaluated yearly to near-adult (final) height, and is herein reported as HSDS; height velocity is also
assessed and reported as a standard deviation score (HVSDS).
Results: Up to August 2015, a total of 186 patients (mean age 10.2 years, 57.5 % males) were enrolled :156 [84 %]
had growth hormone deficiency, 12 [6.5 %] were born small for gestational age, seven [3.8 %] had Prader-Willi
syndrome, one [0.5 %] had Turner syndrome and one [0.5 %] had chronic renal insufficiency; seven [3.8 %] patients had
other indication profiles. The mean treatment duration with Omnitrope® was 28.1 ± 19.1 months. AEs were reported in
35.6 % of patients and included headache, pyrexia, arthralgia, abdominal pain, leg and/or arm pain and increased
blood creatine phosphokinase. Two serious AEs in two patients were thought to be drug-related; one patient
experienced a minimal increase in a known residual craniopharyngioma, and another a gait disturbance with
worsening of walking difficulties. Similar to investigational studies, Omnitrope® treatment was associated with
improvements in both HSDS and HVSDS.
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Conclusions: Omnitrope® appears to be well tolerated and effective for the treatment of a wide range of paediatric
indications, which is consistent with the outcomes from controlled clinical trials. These results need to be interpreted
with caution until the data from the global PATRO Children study are available.
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Background
Over the last 30 years, several recombinant human
growth hormone (rhGH) products have been approved
for the treatment of children with growth disorders asso-
ciated with short stature [1–7], and multiple studies,
both observational and randomized, have established the
efficacy and safety of rhGH products (also known as
somatropin) [8–12].
Omnitrope® (Sandoz, Kundl, Austria), expressed by a
transformed strain of Escherichia coli, was developed
as the biosimilar medicinal product to the originator
Genotropin® (Pfizer Limited, Sandwich, UK) and in
2006 was the first product to be approved by the European
Medicines Agency (EMA) via the European biosimilar
regulatory pathway. Omnitrope® is licensed for use in
treating children with growth hormone deficiency (GHD)
and also those with conditions that can affect growth such
as Turner syndrome (TS), chronic renal insufficiency
(CRI), Prader-Willi syndrome (PWS) and children born
small for gestational age (SGA) [13].
Results from pivotal phase III studies of Omnitrope®
have demonstrated that Omnitrope® is safe and effective
in infants, children and adolescents with GHD [9, 14];
however, more real-world data of Omnitrope® in
pediatric patients are required to consolidate the phase
III outcomes in clinical practice. To address this, the
PAtients TReated with Omnitrope® (PATRO) Children
study was initiated. PATRO Children is a long-term,
post-marketing surveillance (PMS) study investigating
the safety and efficacy of Omnitrope® in children with
growth disturbances. It has been conducted as part of
the risk management plan for Omnitrope®, to fulfil the
commitment with the EMA. Interim 1-year results of
the patients included in this study up to September
2012 (n = 1837) have previously been reported [15] and
annual updates have been presented at international
meetings [16]. Up to January 2016, 4675 patients have
been recruited from 291 sites across 14 countries
(Austria, Czech Republic, France, Germany, Italy,
Poland, Romania, Slovenia, Spain, Sweden, Taiwan,
UK, Canada and USA) in the PATRO Children study.
Herein we present the results of 186 patients recruited
at 17 Italian sites, representing the subgroup of pa-
tients enrolled in Italy since the beginning of the study
up to August 2015.
Methods
Study design
The design of this multicentre, open, longitudinal, non-
interventional PMS study has been published previously
in detail [15]. Briefly, this study was conducted in chil-
dren’s hospitals and specialised endocrinology clinics
in several of the countries where Omnitrope® was
approved. Patients enrolled in the study are infants,
children and adolescents receiving treatment with
Omnitrope® for any diagnosis and who had written in-
formed consent provided by their parents or legal
guardian. Hormone-naïve patients and patients who
had received a previous rhGH were both eligible for inclu-
sion. The study was reviewed and approved by each study
site’s Independent Ethics Committee/Institutional Review
Board, and was conducted in accordance with the Oviedo
Human Right Convention and the Declaration of Helsinki.
Treatment and outcomes
Patients included in the PATRO Children study received
Omnitrope® treatment in accordance with the recom-
mendations in the Summary of Product Characteristics
[13] and/or the prescribing information of the respective
countries. The primary objective of this ongoing observa-
tional study is to collect and analyse the data on long-term
safety of Omnitrope® in infants, children and adolescents
treated within routine clinical practice, with particular
emphasis on the following aspects: diabetogenic potential
of rhGH therapy in children born SGA and treated for
growth disturbance, occurrence of malignancies in rhGH
treated patients, occurrence and clinical implications of
anti-rhGH antibodies and the risks of rhGH treatment in
patients with PWS.
All adverse events (AEs), serious adverse events (SAEs),
adverse drug reactions (ADRs), and serious ADRs were re-
corded in electronic case report forms and entered into
the Sandoz safety database. Laboratory values (including
glucose metabolism) were also recorded at least once a
year during the study.
The secondary objective was to collect and analyse
data on the efficacy of the treatment. Efficacy end-
points include the auxological data height standard
deviation scores (HSDS) and height velocity standard
deviation scores (HVSDS), derived from height mea-
surements [17, 18].
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Statistical analysis
In this interim analysis, statistical calculations were per-
formed using the software package SAS version 9.3.
AEs were coded using Medical Dictionary for Regula-
tory Activities (MedDRA) version 17.1. Concomitant
medication was coded according to World Health
Organization Drug Dictionary (version 14.3) and the
medications were tabulated by Anatomical Therapeutic
Chemical term in their current version. For continu-
ous/quantitative variables, descriptive statistics, includ-
ing the number of data values available, number of data
values missing, arithmetic mean, standard deviation, mini-
mum, median and maximum were calculated. When
appropriate, continuous parameters were compared using
t-tests or Wilcoxon non-parametric tests. For categorical/
qualitative variables, frequency and percentage tables were
generated. When appropriate, categorical data were com-
pared using chi-square or Fisher’s exact tests. Statistical
tests were two-sided at the significance level of 0.05.
Results
Up to August 2015, 186 patients with a mean age of
10.2 years, including 57.5 % male, were enrolled at 17
sites in Italy (Table 1) and had received Omnitrope®
treatment for a mean of 28.3 ± 19.1 months. Most
patients (n = 156; 84.0 %) had GHD, 12 were born SGA
(5.6 %), seven (3.8 %) had PWS, one (0.5 %) had CRI
and another one (0.5 %) had TS; seven (3.8 %) patients
were enrolled with other indication profiles. Overall,
89.8 % of patients were naïve to hormone therapy and
Omnitrope® was prescribed as their first therapy. The
mean duration of growth hormone pre-treatment for all
remaining patients (10.2 %) was similar for all indications
(27.8 ± 19.2 months), with the exception of one patient
with PWS whose pre-treatment period was 47.3 months.
Eighty-five patients had discontinued documentation in
PATRO Children study at the time of this analysis. Rea-
sons for discontinuation included: patient reached final
height/bone age maturation (n = 26; 30.6 %); switch to
other growth hormone products (n = 21; 24.7 %; these pa-
tients, all coming from one site, were switched to other
rhGHs, between November 2011 and January 2012, after
the decision to interrupt data generation); lost to follow-up
(n = 7; 8.2 %); other reasons (n = 6; 7.1 %); AEs (n = 2;
2.4 %); a slowdown of height velocity below 1 cm/year (n =
1; 1.2 %); patient did not wish to continue the injections
(n = 1; 1.2 %) and patient non-compliance (n = 1; 1.2 %).
The reason for discontinuation was unknown in the
remaining 20 patients (23.5 % of patients).
Safety
Up to August 2015, there were 142 AEs registered in the
database occurring in 66 (35.6 %) of the 186 patients
included in the Italian safety analysis set. The most com-
mon AEs reported (incidence > 9.12 over 438.8 patient-
years) were headache (13 patients; 7.0 %; GHD n = 12,
other n = 1), pyrexia (7 patients; 3.8 %; GHD n = 5,
SGA n = 1, CRI n = 1), arthralgia (5 patients; 2.7 %;
GHD n = 5), abdominal pain (4 patients; 2.2 %; GHD
n = 2, SGA n = 1, other n = 1), leg and/or arm pain (4
patients; 2.2 %; GHD n = 3, other n = 1) and increased
blood creatine phosphokinase (4 patients; 2.2 %; GHD
n = 4). Nineteen ADRs occurred in 18 (9.1 %) patients;
one patient experience two events of increased creat-
ine phosphokinase levels. The number of ADRs with
available MedDRA preferred terms was 17 (incidence
> 2.28); these are summarized in Table 2. Two add-
itional ADRs without available MedDRA preferred
terms were reported in patients with GHD; one male
patient had subclinical hyperthyroidism and one
female had high insulin-like growth factor-1 (IGF-1)
levels (667.4 ng/mL).
A total of 10 SAEs in eight (4.3 %) patients were re-
ported. Among these, two SAEs in two GHD patients
were considered possibly related to Omnitrope® treat-
ment. One patient with previous craniopharyngioma (a
19-year-old male) experienced a minimal increase in the
Table 1 Baseline characteristics and demographics of Italian
patients enrolled in the PATRO Children study up to August 2015
Characteristic N = 186
Gender(%)
Male 107 (57.5)
Female 79 (42.5)
Chronological age, years 10.2 ± 3.3
HSDS ± SD −2.29 ± 0.86 (Nmiss = 30)
Height velocity, cm/year ± SD 3.9 ± 2.1 (Nmiss = 91)
BMI, kg/m2 ± SD 17.2 ± 3.6 (Nmiss = 35)
Diagnosis at presentation, n (%)
GHD 156 (84.0)
SGA 12 (6.5)
TS 3 (1.6)
PWS 7 (3.8)
CRI 1 (0.5)
Other 7 (3.8)
Previous treatment status, n (%)
Hormone naïve 167 (89.8)
Pre-treated 19 (10.2)
Omnitrope® dosing at baseline, mg/kg/day 0.032 ± 0.008
Duration of Omnitrope® treatment, months 28.3 ± 19.1
All values are presented as mean ± standard deviation unless otherwise stated
BMI body mass index, CRI chronic renal insufficiency, GHD growth hormone
deficiency, HSDS Height Standard Deviation Scores, Nmiss number of patients
with data missing, PWS Prader-Willi syndrome, SD standard deviation, SGA
small for gestational age, TS Turner syndrome
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size of residual craniopharyngioma 5 years after initi-
ation of Omnitrope®. For safety reasons, Omnitrope® was
discontinued in this patient and restarted 4 months
later; as the increase was not confirmed by a subse-
quent magnetic resonance imaging (MRI) scan, this
event was reported as completely resolved. The second
patient (an 8-year-old male), who had skeletal dysplasia
and syndactyly, experienced a gait disturbance with a
worsening of his walking difficulties. In this patient,
Omnitrope® treatment was permanently discontinued
and the outcome of the event was not reported.
To date, there have been no confirmed cases of type 1
or type 2 diabetes mellitus with Omnitrope® treatment;
however, two patients had mildly impaired glucose toler-
ance. Similar to the global preliminary results, no growth
hormone-related malignancies or investigator-reported
data concerning anti-rhGH antibody titres have been re-
ported. In patients with PWS, four AEs were reported in
two patients; the first patient had one mild AE (bronchitis)
and two SAEs (atelectasis, interstitial lung disease), whilst
the second patient had sleep apnoea syndrome, which was
considered to be drug-related.
Efficacy
With Omnitrope® treatment, HSDS values improved
gradually over time in the total patient population
(Fig. 1a), from a mean HSDS value of –2.29 ± 0.84 (n =
133) at baseline to –1.13 ± 1.15 (n = 21) at Year 4. This
positive trend continued to Year 5 (–0.10 ± 0.58 [n = 10])
and the improvement in HSDS occurred irrespective of
pre-treatment status (Fig. 1b). A similar trend was ob-
served in hormone-naïve patients with GHD (Fig. 2).
Due to the small number of Italian patients with
Table 2 Adverse drug reactions in the safety analysis set (n = 186)
Adverse drug reactiona,b Patients,
n (%)
Incidence
(patient-yearsc = 438.8)
Increased blood creatine
phosphokinase
4 (2.2) 11.4
Impaired glucose tolerance 2 (1.1) 4.56
Craniopharyngioma 1 (0.5) 2.28
Drug administration error 1 (0.5) 2.28
Exostosis 1 (0.5) 2.28
Gait disturbance 1 (0.5) 2.28
Headache 1 (0.5) 2.28
Hyperinsulinism 1 (0.5) 2.28
Increased insulin-like growth factor 1 (0.5) 2.28
Metabolic disorder 1 (0.5) 2.28
Sleep apnoea syndrome 1 (0.5) 2.28
Snoring 1 (0.5) 2.28
aPreferred term/MedDRA dictionary
bMild or moderate
cUntil cut-off date
Fig. 1 Change in height standard deviation scores (HSDS) in (a) the
total efficacy analysis set and (b) pre-treated and naïve patients over
5 years. BL, baseline
Fig. 2 Change in height standard deviation scores (HSDS) in
hormone-naïve patients with growth hormone deficiency (GHD)
included in the efficacy analysis set over 5 years. BL, baseline
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indications other than GHD, the data obtained was not
statistically meaningful.
In hormone-naïve patients, mean HVSDS increased
from a baseline value of –1.49 ± 1.50 (n = 74) to a peak
mean of 2.50 ± 2.17 at 0.5 years (n = 119) and stabilised
to 0.74 ± 0.87 at 4.0 years (n = 20) and 0.63 ± 0.79 at
5.0 years (n = 10; Fig. 3). This trend in HVSDS was also
observed in hormone-naïve patients with GHD (Fig. 3)
and children born SGA (from –1.79 ± 0.82 [n = 4] at
baseline to 1.13 ± 1.23 at 1.5 years [n = 4]).
Discussion
The results of this interim analysis showed that Omni-
trope® was well tolerated and effective in Italian children
with growth disturbances requiring rhGH treatment.
The most common AEs reported were headache, pyr-
exia, arthralgia, abdominal pain and increased blood cre-
atine phosphokinase. ADRs were reported in 9.1 % of
patients and two of these were considered serious.
Some studies have suggested a link between rhGH
treatment and the development of diabetes [19], whilst
other studies have not established the same relationship
[9, 20]. More specifically, children born SGA may be at
increased risk of developing insulin resistance and type 2
diabetes [21] and there is concern that rhGH may amp-
lify this risk. A study based on the Kabi Pharmacia Inter-
national Growth Study (KIGS) database evaluating the
adverse events of rhGH therapy in children with PWS
reported that four patients developed hyperglycaemia
and six patients had presumptive diabetes with therapy
[22]. In accordance with our results, where no cases of
type 1 or type 2 diabetes were reported, the findings
from the Omnitrope® phase III clinical study, as well as
the first data published from the global PATRO Children
study, did not support a link between rhGH treatment
therapy and diabetes [14, 15]; however, the potential
association between rhGH treatment therapy and the
development of diabetes still has to be confirmed in
every day clinical practice.
There is conflicting evidence regarding whether there
is an association between rhGH treatment therapy and
the risk of developing cancer [23]. Concerns emerged
from observations where growth hormone was shown to
raise serum concentrations of IGF-1, as IGF-1exhibits
mitogenic and anti-apoptotic properties in vitro as well
as in animal models [24]. The occurrence of cancer as
well as an increased risk of developing a second malig-
nancy was observed in cancer patients treated with
growth hormone compared with non-treated cancer pa-
tients [24]. However, a study based on the KIGS data-
base reported no association between rhGH therapy and
increased incidence of cancer [25]. In this interim analysis
of Italian data from the PATRO Children study, one patient
presented with an increase of a residual craniopharyngioma
and treatment was temporarily interrupted, although a sub-
sequent MRI scan did not confirm this increase. To further
investigate the incidence of malignancies in this interim
analysis, these findings will need to be compared with
results from the global PATRO Children study. No other
malignancies suspected to be related to the Omnitrope®
treatment were reported, and at data cut-off, there have
been no investigator-reported anti-rhGH antibody titres.
The efficacy data indicate a positive effect of Omni-
trope® on growth parameters in paediatric Italian pa-
tients, confirming the outcomes of the phase III trials.
Similar to investigational studies, Omnitrope® treatment
was associated with an improvement in both HSDS and
HVSDS in paediatric patients with GHD [9, 14]. As ex-
pected, patients who had received rhGH pre-treatment
had a baseline HSDS higher than those who were naïve
to rhGH, but the responses followed the same trend for
the two populations.
A study based on the KIGS database reported a
change in median HSDS in Caucasian patients with
GHD from –2.4 to –0.8 in males and from –2.6 to –1.0
in females following rhGH replacement therapy [26].
These results are similar to the findings reported in this
study, although a comparison is difficult due to the vari-
ation in treatment duration and baseline age. In fact,
analysis of the KIGS database has confirmed an inverse
correlation between age at treatment start and growth
response [26].
The results of this analysis are consistent with those
reported in the global PATRO Children study up to
September 2012 [15]. These data from the PATRO
Children study support that Omnitrope® is well
Fig. 3 Change in height velocity standard deviation scores (HVSDS)
in the total hormone-naïve patient population and in hormone-naïve
patients with growth hormone deficiency (GHD) included in the
efficacy analysis set over 5 years. BL, baseline
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tolerated in routine clinical practice; no confirmed
cases of diabetes, no reports of malignancy and no add-
itional safety issues were reported. However, consider-
ing the August 2015 cut-off date, there are some
differences between the characteristics of the patients
included in the full analysis of the PATRO Children
study and the current analysis of the Italian patients. In
the global analysis, 58.7 % of patients included are
GHD, 25.9 % of the patients were born SGA and the
remaining children are diagnosed with TS (4.4 %), PWS
(2.3 %), CRI (0.7 %) or other diagnosis (6.0 %) [15]. In
contrast, in this Italian analysis the proportion of pa-
tients with GHD is very high (~80 % of patients) whilst
only 6.5 % of patients were born SGA. This may be an
indication of a difference between how the children are
diagnosed and/or treated in Italy compared with the
other countries.
The results of this analysis are also consistent with the
latest data of the overall PATRO Children study, which
was analysed in January 2016 (data on file). In the 4675
patients recruited so far, the mean duration of Omni-
trope® treatment has been 30.2 ± 22.0 months. Overall,
1653 patients (35.4 %) have experienced AEs and 248
(5.3 %) have experienced an SAE; SAEs were considered
treatment-related in 22 (0.5 %) patients. One case of
gradual onset of type 1 diabetes has been reported and
there have been no reports of rhGH-related malignan-
cies or additional safety concerns. Additionally, no clin-
ically relevant positive anti-rhGH antibody titres have
been reported. Efficacy data indicate that Omnitrope®
has a positive effect on growth parameters in children:
after 4 years of treatment, Omnitrope® resulted in sig-
nificant improvements in growth parameters across all
indications, irrespective of gender or pre-treatment sta-
tus. In particular, over the first 4 years of treatment,
greater height gains were observed in hormone-naïve
patients, with a mean HVSDS (SD) of 1.66 (2.67) and
ΔHVSDS +4.56 in patients with GHD (n = 411) and of
0.80 (2.21) and ΔHVSDS +3.41 in children born SGA
(n = 231).
PWS is a rare condition and the PATRO Children
study provides an opportunity to investigate how chil-
dren with PWS respond to rhGH therapy [15]. In this
interim analysis of Italian patients, one patient reported
mild sleep apnoea syndrome, which was considered to
be related to the rhGH therapy. Sleep apnoea has been
reported as a cause of death in a PWS patient treated
with growth hormone therapy in a study based on the
KIGS database [22]. While rhGH therapy appears to be
relatively well tolerated in the overall population of
Italian children with PWS, these results need to be
interpreted with caution due to the small patient num-
ber (n = 7) and will need to be confirmed by the global
analysis of the PATRO Children study, when published.
While the results of this analysis are supportive of the
long-term interventional trials of Omnitrope®, there are
some limitations to the interpretation of these findings.
The patients included in this analysis were mainly diag-
nosed as having GHD which, as mentioned earlier, is not
representative of the results of the therapy in all differ-
ent indications of rhGH treatment. However, we feel that
this study is reflective of the real-world clinical practice
in Italy and may be interpreted as such.
Conclusions
This analysis showed that Omnitrope® is well tolerated
and effective in a wide range of paediatric indications in
routine clinical practice. The safety and efficacy of
Omnitrope®, a somatropin biosimilar, was consistent
with that observed in controlled clinical trials. All these
data can contribute to ruling out the hypothetical con-
cerns related to the use of biosimilars in real-world clin-
ical practice.
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